CureVac’s Public Market Journey Concludes with BioNTech Integration

The independent chapter for CureVac as a publicly traded entity has now closed. The biotechnology firm's shares were formally delisted in mid-January 2026, finalizing its full absorption into industry peer BioNTech.

This move follows the successful completion of a share exchange offer and subsequent corporate reorganization by BioNTech, which resulted in the acquisition of all remaining CureVac equity. The process reached its final administrative stage in early January when Form 25 was filed with the U.S. Securities and Exchange Commission (SEC). The delisting officially took effect on January 16, 2026, retiring the ticker symbol CVAC from the market.

Under the terms of the all-stock transaction, former CureVac shareholders received BioNTech American Depositary Shares (ADSs) based on a predetermined exchange ratio. All CureVac assets are now incorporated within BioNTech's corporate framework.

Should investors sell immediately? Or is it worth buying CureVac?

CureVac's standalone operations have ceased with the acquisition's conclusion, marking a notable consolidation within the mRNA biotechnology sector. BioNTech now holds control over CureVac's proprietary technology platform, including its associated intellectual property and clinical development pipeline.

Market participants who had been monitoring CureVac's research initiatives—encompassing vaccine candidates targeting oncology and infectious diseases—will now need to follow BioNTech's financial disclosures and clinical trial reports for updates. Analysis published on February 2, 2026, suggests BioNTech is actively advancing the integration of these new assets. Market attention is subsequently shifting toward anticipated oncology data from the combined entity, expected later in the year.

Key Transaction Details

• Delisting Effective Date: January 16, 2026
• Acquiring Entity: BioNTech SE (Nasdaq: BNTX)
• Transaction Structure: All-stock acquisition
• Final Regulatory Filing: Form 25 submission on January 6, 2026
• Status of ISIN NL0015436031: Inactive/Delisted

The formal transaction process is now complete. Interested investors will find all future information pertaining to the former CureVac development programs within BioNTech's official corporate communications.